Cambridge Heart Sees Strong Growth, Despite Blue Cross’ Negativity
This article was originally published in The Gray Sheet
Executive Summary
The Blue Cross Blue Shield Association has reaffirmed its negative assessment of microvolt T-wave alternans testing to risk-stratify candidates for ICD therapy, despite accelerating market adoption that is driving sales growth for MTWA test maker Cambridge Heart
You may also be interested in...
T-Wave Alternans ICD Screening May Gain Traction With St. Jude Pact
St. Jude Medical's endorsement of microvolt t-wave alternans testing under a co-marketing agreement with test maker Cambridge Heart will help accelerate adoption of the technology, which guides appropriate defibrillator patient selection, both companies say
Largest-Ever Study Of T-Wave Alternans Greeted With Skepticism
Cambridge Heart hopes results from the largest study of its Microvolt T-Wave Alternans (MTWA) test will increase physician adoption of the technology, though the clinical community is holding out for more data
CMS Proposes National Coverage For Microvolt T-Wave Alternan Testing
Cambridge Heart (HeartWave II) appears to have prevailed in its quest to obtain national coverage for Microvolt T-Wave Alternan testing to evaluate patients at risk of sudden cardiac death, despite opposition from professional societies and the three major ICD firms